Developer docs
API playgroundTry for free, no card

Search company profiles

Liberation Bioindustries

Full company profile

uuid0000kj2

Namestring
Liberation Bioindustries
Legal namestring
Liberation Bioindustries, Inc.
Websiteurl
liberation.bio
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Liberation Bioindustries, formerly Liberation Labs, is a US-based biomanufacturing infrastructure company founded in 2022 that designs, builds, and operates purpose-built precision fermentation facilities as a neutral contract manufacturer. The company's flagship facility in Richmond, Indiana — the first commercial-scale, purpose-built precision fermentation plant of its kind in the US — will offer 600,000 liters of initial fermentation capacity with integrated downstream processing when operations commence in 2026. Liberation serves biotech and consumer-facing companies across food and consumer goods, specialty chemicals and pharmaceuticals, and industrial inputs and advanced materials, offering Biomanufacturing-as-a-Service through long-term take-or-pay agreements and capacity reservations under its proprietary Bio3™ [Design, Build, Operate] platform.

The company's technology stack centers on precision fermentation at industrial scale, using large bioreactors (150,000-liter and 500,000+ liter units) and integrated downstream processing to produce high-value compounds. The Bio3 platform is positioned as a modular, replicable design-build-operate methodology intended for rapid geographic replication. Liberation holds registered trademarks on its brand identity, the Liberation Labs legacy mark, and the Bio3 platform. Its primary physical asset is the Richmond plant, with early-stage engineering underway for a second facility in the Kingdom of Saudi Arabia in partnership with Topian (NEOM Food Company).

Liberation generates revenue through managed-services contract manufacturing fees, with bespoke per-customer pricing negotiated under multi-year take-or-pay agreements and capacity reservation deals. It has secured over 50% of Richmond nameplate capacity under contract or in late-stage agreements, with Vivici (a Dutch ingredients startup producing Vivitein™ BLG dairy protein) named as its first and anchor customer. The company has raised over $376M cumulatively through seed, Series A, equipment financing, USDA-backed debt, and convertible instruments, with key investors including Agronomics, Siddhi Capital, CPT Capital, and the NEOM Investment Fund. Its go-to-market relies on direct enterprise sales supported by thought leadership content via the Inside Biomanufacturing newsletter and industry event participation.

Short descriptiontext

Liberation Bioindustries is a US-based contract manufacturer that designs, builds, and operates purpose-built precision fermentation facilities, serving biotech, food, pharmaceutical, and industrial customers through its Biomanufacturing-as-a-Service model anchored by a 600,000-liter Richmond, Indiana plant.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision fermentation, contract biomanufacturing, biomanufacturing infrastructure, industrial biotechnology, fermentation capacity services
Industry3 codes
1Biorefinery Technology & Contract Processing (fractionation, tolling, scale-up)
CodeIMAMALALPrimaryYes
2Biofuels & Renewable Fuels Switching (Biomethane/RNG, Bio-oils, Sustainable Biomass)
CodeEUABAJADPrimaryNo
3Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery)
CodeHLAAAFAJPrimaryNo
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Food And Kindred Products2000
  • Biological Products, (No Disgnostic Substances)2836
Product category
Contract Biomanufacturing / Precision Fermentation Services
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Contract Manufacturing (BaaS)
TypeManaged Services
Description

Liberation operates as a contract manufacturer offering Biomanufacturing-as-a-Service (BaaS) through long-term partnerships and take-or-pay agreements. Customers gain capital-light access to world-class fermentation and purification capacity, backed by robust quality systems, feedstock sourcing, and production reliability. The company provides design, build, and operate services for precision fermentation infrastructure.

liberation.bio
2Capacity Reservation Agreements
TypeManaged Services
Description

Capacity reservations allow customers to secure fermentation capacity in advance, providing revenue visibility and ensuring production slots are available when needed.

liberation.bio
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Infrastructure, Operations, Personnel, Technology or R&D, Supply Chain, Marketing or Sales
Pricing details1 tier
1Custom contract manufacturing services with bespoke pricing
ModelOtherBilling cadenceMulti-year contract
Notes

Long-term take-or-pay agreements and capacity reservation options. Pricing is negotiated on a per-customer basis as a contract manufacturer offering bespoke biomanufacturing services.

liberation.bio
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Liberation Bioindustries is a contract manufacturer offering Biomanufacturing-as-a-Service (BaaS) through purpose-built, commercial-scale precision fermentation facilities. The company produces specialized ingredients for customers across food, pharmaceuticals, specialty chemicals, plastics, biofuels, and other sectors using its proprietary Bio3 Design-Build-Operate platform, with 600,000+ liters of initial fermentation capacity and integrated downstream processing.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Over 50% of nameplate capacity at the Richmond plant under contract or in late stages of agreements
+1 more record
Product and service2 records
1Biomanufacturing-as-a-Service (BaaS) Contract Manufacturing
CategoryContract Biomanufacturing Services
Description

End-to-end contract manufacturing service that produces specialized ingredients via precision fermentation at commercial scale, providing customers with design, build, and operate capacity without the capital outlay of building their own facilities. Long-term partnerships and take-or-pay agreements give customers access to 600,000+ liters of fermentation capacity, integrated downstream processing, robust quality systems, feedstock sourcing, and production reliability.

2Capacity Reservation Agreements
CategoryContract Manufacturing / Capacity Booking
Description

A reservation product that lets customers secure fermentation production slots at Liberation's facilities in advance, providing committed capacity, revenue visibility, and prioritized scheduling for their precision-fermented product programs.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-05-07
Description

Liberation Bioindustries partnered with Vivici, a Dutch ingredients startup, to manufacture commercial scale volumes of Vivitein™ BLG (beta-lactoglobulin), a dairy protein. This is Liberation's first customer for its Richmond plant, with over 50% of nameplate capacity contracted or in late stages of agreement. The partnership addresses growing global protein demand through precision fermentation.

2Topian (NEOM Food Company)
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-04-16
Description

Strategic partnership with Topian - The NEOM Food Company to design and develop an advanced precision fermentation facility in the Kingdom of Saudi Arabia. This project represents a critical step in Liberation's global expansion, supporting regional food security and sustainable production goals through precision fermentation. Planning is currently underway.

liberation.bio
Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2024-01-09
Description

Partnership to train the biomanufacturing workforce of the future. Ivy Tech Community College provides educational programs and training to support Liberation's workforce needs as the company scales operations in Indiana.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-06-29
Description

Partnership through the Purdue President's Council, empowering the next generation of innovators through alumni engagement and advancement of higher education. Purdue is also a partner in Heartland BioWorks, the Regional Technology and Innovation Tech Hub designated by the U.S. Economic Development Administration focused on bioproduction.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-24
Description

Liberation's Richmond facility is part of the Indiana Regional Technology and Innovation Tech Hub designated by the U.S. Economic Development Administration in 2023, focused on bioproduction. Heartland BioWorks leads the consortium in partnership with Purdue University, Indiana University, and other organizations.

Recent move14 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Australia-based precision fermentation contract manufacturer building large-scale fermentation capacity for partners. Directly comparable to Liberation as a CDMO scaling precision fermentation for food, materials and chemicals customers.

TypeDirect peer
Description

US-based fermentation CDMO offering bioreactor capacity and bioprocess services to biotech customers. Directly comparable as a contract fermentation manufacturer targeting similar customer profiles.

TypeDirect peer
Description

US precision fermentation company producing animal-free proteins for food and beauty. Comparable in that Geltor operates large-scale precision fermentation for ingredient commercialization, though vertically integrated rather than pure CDMO.

TypeBroad incumbent
Description

US precision fermentation leader producing animal-free whey protein. Comparable as a precision fermentation operator at commercial scale in food ingredients, though operates its own brands rather than acting primarily as a CDMO.

TypeEmerging player
Description

German precision fermentation startup producing animal-free dairy proteins (casein, whey). Comparable target end-markets and use of precision fermentation; emerging player that could become a Liberation customer or competitor.

TypeEmerging player
Description

US precision fermentation company producing animal-free egg and protein ingredients. Comparable as a precision fermentation ingredient producer with similar target customers (food CPG) and technology base.

TypeEmerging player
Description

US precision fermentation startup producing casein for dairy cheese applications. Comparable technology and target end-market (animal-free dairy) as Liberation's Vivici customer use case.

TypeBroad incumbent
Description

US biomanufacturing CDMO offering end-to-end manufacturing services across biologics and advanced therapies. Comparable as a broader biomanufacturing services provider though focused on pharma rather than food/precision fermentation.

TypeEmerging player
Description

Dutch precision fermentation startup producing beta-lactoglobulin dairy protein. Liberation's anchor customer and a comparable precision fermentation ingredient company in the same end-market and technology category.

TypeOthers
Description

US Department of Defense-sponsored biomanufacturing innovation institute that operates a Pilot Plant Network. A declared Liberation partner and ecosystem enabler; not a competitor but a comparable node in the US biomanufacturing infrastructure landscape.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Liberation Bioindustries

Contract Biomanufacturing / Precision Fermentation Servicesliberation.bio

Liberation Bioindustries is a US-based contract manufacturer that designs, builds, and operates purpose-built precision fermentation facilities, serving biotech, food, pharmaceutical, and industrial customers through its Biomanufacturing-as-a-Service model anchored by a 600,000-liter Richmond, Indiana plant.

What Liberation Bioindustries does

Liberation Bioindustries, formerly Liberation Labs, is a US-based biomanufacturing infrastructure company founded in 2022 that designs, builds, and operates purpose-built precision fermentation facilities as a neutral contract manufacturer. The company's flagship facility in Richmond, Indiana — the first commercial-scale, purpose-built precision fermentation plant of its kind in the US — will offer 600,000 liters of initial fermentation capacity with integrated downstream processing when operations commence in 2026. Liberation serves biotech and consumer-facing companies across food and consumer goods, specialty chemicals and pharmaceuticals, and industrial inputs and advanced materials, offering Biomanufacturing-as-a-Service through long-term take-or-pay agreements and capacity reservations under its proprietary Bio3™ [Design, Build, Operate] platform.

The company's technology stack centers on precision fermentation at industrial scale, using large bioreactors (150,000-liter and 500,000+ liter units) and integrated downstream processing to produce high-value compounds. The Bio3 platform is positioned as a modular, replicable design-build-operate methodology intended for rapid geographic replication. Liberation holds registered trademarks on its brand identity, the Liberation Labs legacy mark, and the Bio3 platform. Its primary physical asset is the Richmond plant, with early-stage engineering underway for a second facility in the Kingdom of Saudi Arabia in partnership with Topian (NEOM Food Company).

Liberation generates revenue through managed-services contract manufacturing fees, with bespoke per-customer pricing negotiated under multi-year take-or-pay agreements and capacity reservation deals. It has secured over 50% of Richmond nameplate capacity under contract or in late-stage agreements, with Vivici (a Dutch ingredients startup producing Vivitein™ BLG dairy protein) named as its first and anchor customer. The company has raised over $376M cumulatively through seed, Series A, equipment financing, USDA-backed debt, and convertible instruments, with key investors including Agronomics, Siddhi Capital, CPT Capital, and the NEOM Investment Fund. Its go-to-market relies on direct enterprise sales supported by thought leadership content via the Inside Biomanufacturing newsletter and industry event participation.

Liberation Bioindustries firmographics

Firmographics
Name
Liberation Bioindustries
Legal name
Liberation Bioindustries, Inc.
Website
https://liberation.bio
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
11–50 employees
Short description
Liberation Bioindustries is a US-based contract manufacturer that designs, builds, and operates purpose-built precision fermentation facilities, serving biotech, food, pharmaceutical, and industrial customers through its Biomanufacturing-as-a-Service model anchored by a 600,000-liter Richmond, Indiana plant.
Ownership category
akta.pro rank

Liberation Bioindustries industry classification

Industry
Product category
Contract Biomanufacturing / Precision Fermentation Services
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Food And Kindred Products (2000), Biological Products, (No Disgnostic Substances) (2836)
akta.pro primary industry
Biorefinery Technology & Contract Processing (fractionation, tolling, scale-up) (IMAMALAL)
akta.pro secondary industries
Biofuels & Renewable Fuels Switching (Biomethane/RNG, Bio-oils, Sustainable Biomass) (EUABAJAD), Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery) (HLAAAFAJ)

Keywords

  • Precision fermentation
  • Contract biomanufacturing
  • Biomanufacturing infrastructure
  • Industrial biotechnology
  • Fermentation capacity services

Where Liberation Bioindustries is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Liberation Bioindustries business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Infrastructure, Operations, Personnel, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

  1. Contract Manufacturing (BaaS): Liberation operates as a contract manufacturer offering Biomanufacturing-as-a-Service (BaaS) through long-term partnerships and take-or-pay agreements. Customers gain capital-light access to world-class fermentation and purification capacity, backed by robust quality systems, feedstock sourcing, and production reliability. The company provides design, build, and operate services for precision fermentation infrastructure.
  2. Capacity Reservation Agreements: Capacity reservations allow customers to secure fermentation capacity in advance, providing revenue visibility and ensuring production slots are available when needed.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom contract manufacturing services with bespoke pricing

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Liberation Bioindustries product offering

Product offering

Core offering

Liberation Bioindustries is a contract manufacturer offering Biomanufacturing-as-a-Service (BaaS) through purpose-built, commercial-scale precision fermentation facilities. The company produces specialized ingredients for customers across food, pharmaceuticals, specialty chemicals, plastics, biofuels, and other sectors using its proprietary Bio3 Design-Build-Operate platform, with 600,000+ liters of initial fermentation capacity and integrated downstream processing.

Differentiator

Problem solved

Functional benefit

Products and services

  • Biomanufacturing-as-a-Service (BaaS) Contract Manufacturing End-to-end contract manufacturing service that produces specialized ingredients via precision fermentation at commercial scale, providing customers with design, build, and operate capacity without the capital outlay of building their own facilities. Long-term partnerships and take-or-pay agreements give customers access to 600,000+ liters of fermentation capacity, integrated downstream processing, robust quality systems, feedstock sourcing, and production reliability.
  • Capacity Reservation Agreements A reservation product that lets customers secure fermentation production slots at Liberation's facilities in advance, providing committed capacity, revenue visibility, and prioritized scheduling for their precision-fermented product programs.

Quantifiable outcome

  • Over 50% of nameplate capacity at the Richmond plant under contract or in late stages of agreements
  • +1 more outcomes

Companies that use Liberation Bioindustries

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Liberation Bioindustries technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Liberation Bioindustries partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and flagship.

  • VivicicoreChannel Partner/ Reseller/ Distributor · 7 May 2025Liberation Bioindustries partnered with Vivici, a Dutch ingredients startup, to manufacture commercial scale volumes of Vivitein™ BLG (beta-lactoglobulin), a dairy protein. This is Liberation's first customer for its Richmond plant, with over 50% of nameplate capacity contracted or in late stages of agreement. The partnership addresses growing global protein demand through precision fermentation.
  • Topian (NEOM Food Company)flagshipStrategic or Co-development Partner · 16 April 2025Strategic partnership with Topian - The NEOM Food Company to design and develop an advanced precision fermentation facility in the Kingdom of Saudi Arabia. This project represents a critical step in Liberation's global expansion, supporting regional food security and sustainable production goals through precision fermentation. Planning is currently underway.
  • Ivy Tech Community CollegecoreImplementation/ SI/ Consulting Partner · 9 January 2024Partnership to train the biomanufacturing workforce of the future. Ivy Tech Community College provides educational programs and training to support Liberation's workforce needs as the company scales operations in Indiana.
  • Purdue UniversitycoreStrategic or Co-development Partner · 29 June 2023Partnership through the Purdue President's Council, empowering the next generation of innovators through alumni engagement and advancement of higher education. Purdue is also a partner in Heartland BioWorks, the Regional Technology and Innovation Tech Hub designated by the U.S. Economic Development Administration focused on bioproduction.
  • Heartland BioWorks / U.S. Economic Development AdministrationcoreStrategic or Co-development Partner · 24 January 2023Liberation's Richmond facility is part of the Indiana Regional Technology and Innovation Tech Hub designated by the U.S. Economic Development Administration in 2023, focused on bioproduction. Heartland BioWorks leads the consortium in partnership with Purdue University, Indiana University, and other organizations.

Scale indicators6 records

Recent moves14 records

Expansion highlights6 records

Liberation Bioindustries competitors and assessment

Company assessment

Direct peers

  • Cauldron: Australia-based precision fermentation contract manufacturer building large-scale fermentation capacity for partners. Directly comparable to Liberation as a CDMO scaling precision fermentation for food, materials and chemicals customers.
  • Culture Biosciences: US-based fermentation CDMO offering bioreactor capacity and bioprocess services to biotech customers. Directly comparable as a contract fermentation manufacturer targeting similar customer profiles.
  • Geltor: US precision fermentation company producing animal-free proteins for food and beauty. Comparable in that Geltor operates large-scale precision fermentation for ingredient commercialization, though vertically integrated rather than pure CDMO.

Broad incumbents

  • Perfect Day: US precision fermentation leader producing animal-free whey protein. Comparable as a precision fermentation operator at commercial scale in food ingredients, though operates its own brands rather than acting primarily as a CDMO.
  • Resilience: US biomanufacturing CDMO offering end-to-end manufacturing services across biologics and advanced therapies. Comparable as a broader biomanufacturing services provider though focused on pharma rather than food/precision fermentation.

Emerging players

  • Formo: German precision fermentation startup producing animal-free dairy proteins (casein, whey). Comparable target end-markets and use of precision fermentation; emerging player that could become a Liberation customer or competitor.
  • The EVERY Company: US precision fermentation company producing animal-free egg and protein ingredients. Comparable as a precision fermentation ingredient producer with similar target customers (food CPG) and technology base.
  • New Culture: US precision fermentation startup producing casein for dairy cheese applications. Comparable technology and target end-market (animal-free dairy) as Liberation's Vivici customer use case.
  • Vivici: Dutch precision fermentation startup producing beta-lactoglobulin dairy protein. Liberation's anchor customer and a comparable precision fermentation ingredient company in the same end-market and technology category.

Others

  • BioMADE: US Department of Defense-sponsored biomanufacturing innovation institute that operates a Pilot Plant Network. A declared Liberation partner and ecosystem enabler; not a competitor but a comparable node in the US biomanufacturing infrastructure landscape.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Liberation Bioindustries social profiles

Digital presence

Liberation Bioindustries financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Liberation Bioindustries leadership team

Management profile

Number of profiles

Profiles8 records

Liberation Bioindustries funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Liberation Bioindustries M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Liberation Bioindustries

What does Liberation Bioindustries do?

Liberation Bioindustries is a contract manufacturer offering Biomanufacturing-as-a-Service (BaaS) through purpose-built, commercial-scale precision fermentation facilities. The company produces specialized ingredients for customers across food, pharmaceuticals, specialty chemicals, plastics, biofuels, and other sectors using its proprietary Bio3 Design-Build-Operate platform, with 600,000+ liters of initial fermentation capacity and integrated downstream processing.

Is Liberation Bioindustries a public or private company?

Liberation Bioindustries is a private company. It is classified as venture growth investor backed and is currently operating.

When was Liberation Bioindustries founded?

Liberation Bioindustries was founded in 2022. It employs 11 to 50 people.

Where is Liberation Bioindustries based?

Liberation Bioindustries is headquartered in New York, United States, in the North America region.

How does Liberation Bioindustries make money?

Two revenue lines are on record. Contract Manufacturing (BaaS) is the primary driver. The others are capacity Reservation Agreements.

Who are Liberation Bioindustries's main competitors?

Direct peers on record are Cauldron, Culture Biosciences and Geltor. Broad incumbents are Perfect Day and Resilience. Emerging players are Formo, The EVERY Company, New Culture and Vivici. BioMADE is listed as an others.

Does Liberation Bioindustries have an API?

No public API is recorded for Liberation Bioindustries.

What industry is Liberation Bioindustries in?

Liberation Bioindustries's product category is Contract Biomanufacturing / Precision Fermentation Services. Its primary akta.pro industry code is IMAMALAL, Biorefinery Technology & Contract Processing (fractionation, tolling, scale-up), with a secondary code of EUABAJAD, Biofuels & Renewable Fuels Switching (Biomethane/RNG, Bio-oils, Sustainable Biomass). Its NAICS code is 325414 and its SIC code is 2000.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comAgronomics portfolio company Liberation Bioindustries seeks $25m By Investing.comLiberation Bioindustries, a portfolio company of Agronomics, needs about $25 million to finish its Richmond facility after expected financing failed. The company expects six months to complete and commission the facility, with completion now pushed beyond Q4 2026. It is seeking additional equity, debt, grants, and pre-payments, aiming for a full package by H1 2027.Investing.comLatest Company News - Investing.comLiberation Bioindustries, a portfolio company of Agronomics, requires about $25 million in additional funding to complete its Richmond facility. The company has deployed roughly $125 million to date, and completion is now expected six months after funding is secured, with a full package targeted in the first half of 2027.InvestegateUpdate on Liberation BioindustriesAgronomics announced that its portfolio company Liberation Bioindustries faces a $25 million funding gap to complete its Richmond facility. No acceptable offers were received for a sale or joint venture, so Liberation will proceed independently. Completion is now expected six months after securing additional funding, anticipated in H1 2027.AgFunderNewsLiberation Bioindustries pauses construction again as it seeks funds to complete US biomanufacturing siteLiberation Bioindustries has paused construction of its 600,000-liter precision fermentation facility in Richmond, Indiana, for the second time as it seeks additional funding to complete the project, which is approximately 75% complete and was originally scheduled to be operational by end of 2024. The company reports qualified interest exceeding available capacity by over 200%, but faces a chicken-and-egg financing challenge where customers want operational certainty before committing while capital providers require firm commitments first. The CTO is stepping back from his full-time role as the firm works to secure financing for the finishing touches to the facility.Fastdata极数Ningbo Biological Circular Agriculture Technology Application Service Provider Zhejiang Guangxinyao Bio Completed 50 Million Yuan Series A Financing - FastdataZhejiang Guangxinyao Bio, a provider of biological circular agriculture technology, completed a 50 million yuan Series A financing. The round was jointly invested by green agriculture and biological sci-tech capital, supporting its earthworm circular breeding and agricultural solid waste resource utilization business model.GlobeNewswireLiberation Bioindustries Announces New Roles for FoundersLiberation Bioindustries announced its co-founders swapped roles, with Etan Bendheim becoming CEO and Mark Warner becoming CTO. The company is nearing completion of its first precision fermentation plant in Richmond, Indiana, with over 50% of capacity under contract. Planning is underway for a second plant in Saudi Arabia.Towards HealthcareMicrobial Fermentation Technology Market Grows to USD 67.4 Bn by 2035The global microbial fermentation technology market is projected to grow from USD 38.21 billion in 2025 to USD 67.4 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.84% over the forecast period. Key drivers of this growth include increasing demand for biologics, advancements in genetic engineering and synthetic biology, and rising adoption of sustainable fermentation methods across the pharmaceutical, food, and biofuel sectors. Asia Pacific led the market with 47% revenue share in 2023, while North America is expected to grow at the fastest rate, with significant investments including a $25 million USDA loan to Liberation Labs and $40 million in DARPA funding for fermentation research.SecSEC FORM DLiberation Bioindustries, Inc. filed a Form D notice with the SEC for an exempt offering of equity securities under Rule 506(b), with a total offering amount of approximately $101.7 million. As of November 2025, the company had sold $60.2 million in securities to 7 investors, with $41.5 million remaining to be sold. The Delaware-incorporated company, based at 14 Wall Street in New York, operates in the biotechnology and other technology sectors.BioPharma DiveFrom feedstocks to infrastructure, Indiana’s bioeconomy is on the moveIndiana is positioning itself to become a leading destination for bioinnovators and biomanufacturers by leveraging its agricultural strengths, including 14.5 million acres of farmland and status as the fourth-largest soybean and fifth-largest corn producer in the United States. The state's bioeconomy ecosystem combines established industry leaders like Corteva Agriscience with emerging companies such as Liberation Bioindustries, which broke ground on a precision fermentation facility in 2023. In 2023, the U.S. Economic Development Administration designated Indiana as a Regional Technology and Innovation Tech Hub focused on bioproduction, led by Heartland BioWorks in partnership with Purdue University, Indiana University, and other organizations.GlobeNewswireLiberation Labs Announces Manufacturing Partnership with ViviciLiberation Labs announced a manufacturing partnership with Dutch ingredients startup Vivici to produce Vivici's flagship ingredient, Vivitein BLG, at its Richmond, Indiana facility. Commercial production is scheduled to begin in 2026, with the plant having a 600,000-liter capacity. The partnership expands Vivici's European manufacturing capabilities and US supply security.